Seelos Therapeutics (DB:NXE) - Cotización, noticias y análisis

Resumen acción NXE

Seelos Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica centrada en el desarrollo y la comercialización de terapias para el tratamiento del sistema nervioso central, las vías respiratorias y otros trastornos.

Acerca de la empresa

NXE fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Recompensas

Análisis de riesgos

Acciones altamente ilíquidas

Patrimonio neto negativo

Los accionistas han sido diluidos sustancialmente en el último año

No tiene una capitalización de mercado significativa (€12M)

+ 2 riesgos adicionales

Competidores de Seelos Therapeutics, Inc.

Biofrontera

XTRA:B8F

€21.7m

SynBiotic

DUSE:SBX

€46.8m

Apontis Pharma

XTRA:APPH

€71.6m

Pierrel

DB:2FJ0

€92.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Seelos Therapeutics
Historical stock prices
Current Share Price	US$3.37
52 Week High	US$43.23
52 Week Low	US$3.26
Beta	1.86
1 Month Change	0%
3 Month Change	-22.91%
1 Year Change	-82.62%
3 Year Change	-95.24%
5 Year Change	-92.89%
Change since IPO	-96.76%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	NXE	DE Pharmaceuticals	Mercado DE
7D	0%	-1.0%	-1.7%
1Y	-82.6%	-30.1%	1.4%

Rentabilidad vs. Industria: NXE obtuvo unos resultados inferiores a los del sector German Pharmaceuticals , que el año pasado arrojó un rendimiento del -30.7%.

Rentabilidad vs. Mercado: NXE obtuvo unos resultados inferiores a los del mercado German, que fue del -1.4% el año pasado.

Volatilidad de los precios

Is NXE's price volatile compared to industry and market?
NXE volatility
NXE Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	9.8%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: El precio de las acciones de NXE ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de NXE en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2016	16	Raj Mehra	seelostherapeutics.com

Seelos Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica centrada en el desarrollo y la comercialización de terapias para el tratamiento de trastornos del sistema nervioso central, respiratorios y de otro tipo. Los principales programas de la compañía son SLS-002, una ketamina racémica intranasal para el tratamiento de la ideación suicida aguda y el comportamiento en pacientes con trastornos depresivos mayores; SLS-005, un estabilizador de proteínas para el tratamiento de la esclerosis lateral amiotrófica y el síndrome de Sanfilippo; y SLS-006, un agonista parcial de la dopamina para el tratamiento de pacientes con enfermedad de Parkinson (EP). Sus programas preclínicos incluyen SLS-007, un inhibidor peptídico para tratar a pacientes con EP; SLS-008 para el tratamiento de indicaciones pediátricas; SLS-004 para el tratamiento de la EP; SLS-010, un antagonista del receptor H3; y SLS-012.

Resumen de fundamentos de Seelos Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Seelos Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de NXE
Capitalización bursátil	€10.47m
Beneficios(TTM)	-€47.21m
Ingresos (TTM)	€1.43m

8.8x

Ratio precio-ventas (PS)

-0.3x

Ratio precio-beneficio (PE)

¿Está NXE sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NXE
Ingresos	US$1.55m
Coste de los ingresos	US$0
Beneficio bruto	US$1.55m
Otros gastos	US$52.64m
Beneficios	-US$51.09m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-3.73
Margen bruto	100.00%
Margen de beneficio neto	-3,295.87%
Ratio deuda/patrimonio	-55.5%

¿Cómo se ha desempeñado NXE a largo plazo?

Ver rendimiento histórico y comparativa

Resumen acción NXE

Recompensas

Análisis de riesgos

Competidores de Seelos Therapeutics, Inc.

XTRA:B8F

€21.7m

DUSE:SBX

€46.8m

XTRA:APPH

€71.6m

DB:2FJ0

€92.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Founder recently bought €92k worth of stock

New major risk - Market cap size

Recent updates

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Founder recently bought €92k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought €51k worth of stock

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Director Judith Dunn has left the company

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000004 million.

Seelos Therapeutics, Inc. Announces Positive Data from the Open-Label Study of SLS-002

Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)

New 90-day high: €3.20

New 90-day high: €1.60

Seelos Therapeutics, Inc. Announces Dosing of the First Patients in its Registrational Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior

Seelos Therapeutics Regains Compliance with Minimum Bid Price Requirement

New 90-day high: €1.33

Seelos Therapeutics, Inc. announced that it has received $10 million in funding from The Lind Partners, LLC

New 90-day high: €0.93

Revenue in line with expectations

Seelos Therapeutics, Inc. Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.00335 million.

New 90-day low - €0.56

New 90-day low - €0.70

Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from Russell Microcap Value Index

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Seelos Therapeutics, Inc.

8.8x

-0.3x

Beneficios e Ingresos